Objective: 1) To report on the results and complications arising from using a minimal tissue removal procedure for the placement of an osseointegrated hearing implant. 2) To understand the advantages and disadvantages for this technique compared to the more standard techniques.
Objective: 1) To report on the results and complications arising from using a minimal tissue removal procedure for the placement of an osseointegrated hearing implant. 2) To understand the advantages and disadvantages for this technique compared to the more standard techniques.
Method: Retrospective study in tertiary academic center of all patients undergoing minimally invasive single-stage osseointegrated implant surgery (BAHA®) from 2008-2010. Technique: A small incision (1.5 cm) with little to no soft tissue (fat only) removal with good skin to periosteum fixation after placement of a 4 mm screw and 8.5 mm abutment.
Results: Thirty-three patients were assessed (aged 16-86, range of follow-up 18-45 months). No patients experienced hair loss, significant numbness, cosmetic defects, intraoperative complications, or audiologic complications. Seven patients required some combination of bactroban, steroid ointment, and/or oral antibiotic for mild erythema around the abutment in the first 2 months postop. Two patients required conservative management for delayed skin reactions (3.5 months and 2.5 years). Five of these 6 patients had 1 more episode requiring similar treatment. All reactions resolved in approximately 2-4 weeks. Two additional patients required minor surgical soft tissue revision.
Conclusion:
We have demonstrated comparable outcomes to other surgical techniques with less cosmetic and other associated complaints. This study indicates that a less invasive approach for the surgical implantation of the osseointegrated auditory implant may have merit.
Otology/Neurotology Mining immune Epitopes in Ménière's Disease and Sudden Sensorineural Hearing loss
Michael P. Platt, MD (presenter); Alphi P. Elackattu, MD; Sonam Dilwali; Jignesh Parikh; Konstantina M. Stankovic, MD, PhD Objective: Etiologies for Ménière's disease and sudden sensorineural hearing loss remain unknown. Indirect evidence exists for allergy-mediated or autoimmune process. The purpose of this study is to determine whether immunogenic proteins share similar sequences with inner ear proteins, which may lead to cross-reactivity and immune activation in inner ear disorders.
Method: Comprehensive bioinformatic primary sequence analyses of intact and mutated proteins associated with human syndromic and nonsyndromic hearing loss and proteins expressed in the human inner ear was performed. Comparison of sequences to epitopes in the Immune Epitope Database was performed by exact match, BLAST, and BLOSUM62 score computational algorithms.
Results: Computational analysis of primary protein sequence for 81 known inner ear proteins, 102 proteins from genes identified in syndromic and non-syndromic hearing loss, and 438 protein sequences with known mutations that contribute to sensorineural hearing loss was compared to 151,086 epitopes previously implicated in allergic, autoimmune, and infectious disorders within the Immune Epitope Database. The exact match and BLAST algorithms identified 1925 and 97 unique epitope matches, respectively. Top BLOSUM62 score algorithm resulted in a single hit for the 47 kDa membrane antigen. Other epitopes included those seen in allergic rhinitis, infectious diseases, and autoimmune disorders.
Conclusion: Abnormal immune activation is suspected in
Ménière's disease and SSNHL. Candidate immune epitopes were identified that may contribute to pathogenesis of these disorders. While these epitopes await clinical validation, they present novel targets for diagnosis and treatment of sensorineural hearing loss.
Otology/Neurotology
Monaural Hearing before/after Sequential Cochlear implants Stanley Pelosi, MD (presenter); George B. Wanna, MD; Allyson Sisler-Dinwiddie; Alejandro Rivas, MD; Robert F. Labadie, MD, PhD; Marc L. Bennett, MD; David S. Haynes, MD Objective: The relationship between pre-and postimplantation monaural auditory performance in patients undergoing bilateral sequential cochlear implantation (SCI) has not been clearly defined. A greater understanding of this relationship could potentially affect preoperative counseling to patients regarding choice of initial side to implant.
Method:
Retrospective review was performed of monaural auditory performance pre-and postimplantation in 90 SCI recipients between 1997 and 2011 at Vanderbilt University. A "better-hearing ear" had lower pure tone average or speech awareness threshold by at least 10 dB, or open/closed-set speech perception score at least 10% higher.
Results:
A difference in preimplantation hearing status was identified in 35 patients. The first-implanted ear was betterhearing in 11 and worse-hearing in 24. 28/35 patients had available data on post-implantation monaural auditory performance. At last follow-up (mean 24 months, range 1-69), the first-implanted ear exhibited better closed/open-set speech perception scores in 19/28 (68%) patients. There were no differences when comparing patients grouped according to preimplantation hearing status (Fisher's exact test, P < .05). Median time between implant activations was 31 months when the first-implanted ear exhibited better performance, and 17 when the second-implanted ear performed better (difference NS, rank sum test).
